Results 251 to 260 of about 6,202,090 (405)

Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer

open access: yesMolecular Oncology, Volume 19, Issue 5, Page 1452-1470, May 2025.
Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti   +8 more
wiley   +1 more source

Dysregulated calcium signaling in the aged macaque entorhinal cortex associated with tau hyperphosphorylation. [PDF]

open access: yesFront Aging Neurosci
Bathla S   +7 more
europepmc   +1 more source

Calexcitin: A signaling protein that binds calcium and GTP, inhibits potassium channels, and enhances membrane excitability

open access: green, 1996
Thomas J. Nelson   +13 more
openalex   +1 more source

Calcium compartments in vascular smooth muscle cells as detected by aequorin signal [PDF]

open access: green, 1995
Fujio Abe   +3 more
openalex   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds

open access: yesMolecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.
FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy